PTJ
CTMX icon

Paul Tudor Jones’s CytomX Therapeutics CTMX Stock Holding History

Paul Tudor Jones’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$189K Buy
+50,300
New +$192K ﹤0.01% 3342

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Paul Tudor Jones's CTMX Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 1,380,687 shares worth $5.18M. The stake represents 0.01% of the portfolio and ranks #1257 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in CTMX as recently as Q1 2024.

Paul Tudor Jones first reported a position in CTMX in Q4 2019 and has held it in 15 quarters since. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Paul Tudor Jones held 1,380,687 shares of CytomX Therapeutics worth $5.18M as of Q2 2026.
  • CytomX Therapeutics was a new Paul Tudor Jones position in Q2 2026.
  • CytomX Therapeutics made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1257 holding.
  • Paul Tudor Jones first reported a position in CytomX Therapeutics in Q4 2019 and has held it in 15 quarters since.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.